MedTrace Logo

Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.

NCT01667224 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-02-23

Study results available
· View outcomes & findings →

Summary

Obesity is a major health issue worldwide; there is a constant raise in obesity related death each year. In vitro and animal studies elucidated Actiponin as a novel anti-obesity agent. However, the efficacy and safety of Actiponin supplementation on body weight regulation in humans are lacking.

Conditions

Interventions

DIETARY_SUPPLEMENT

Actiponin

The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.

DIETARY_SUPPLEMENT

Placebo

Amount and calorie of placebo are same with Actiponin.

Sponsors & Collaborators

  • Chonbuk National University Hospital

    lead OTHER

Principal Investigators

  • Soo-Wan Chae, Ph.D, MD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-08-31
Completion
2010-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667224 on ClinicalTrials.gov